Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Roche Receives FDA Approval for Complementary PD-L1 (SP263) Biomarker Test in Urothelial Carcinoma

americanpharmaceuticalreviewMay 09, 2017

Tag: Roche , immunotherapy

PharmaSources Customer Service